February is Black History Month — an important time to highlight the fact that African-Americans are twice as likely to develop dementia as whites and less likely to have a diagnosis. African-Americans are also greatly underrepresented in clinical trials, which are critical to finding methods of prevention, treatment and eventually, a cure for Alzheimer’s.
Currently, more than 90 percent of participants in Alzheimer’s disease trials are white. The Alzheimer’s Association® is seeking to change this disparity by recruiting more African-Americans to participate in Alzheimer’s Association TrialMatch®, a free clinical studies matching service for individuals living with dementia, caregivers and healthy volunteers. TrialMatch is easy to use ― it takes only minutes to create a confidential user profile and receive a customized list of studies that may be a match.
Diverse research participants can help scientists understand why some groups are at a higher risk, how ethnicity may affect health outcomes and why some groups may metabolize drugs differently. In addition, participants in clinical trials receive a high level of care and have a chance to receive cutting-edge treatments.
Alzheimer’s clinical trials need diverse participants to help ensure that advances can benefit all those affected. For more information, visit TrialMatch or call 800.272.3900.